CTMX Q1 2019 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+107.9% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$17M-56.2% margin

Net Income

-$14M-47.9% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+157.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$445M

Total Liabilities

$322M

Stockholders' Equity

$123M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$14M	+107.9%
Gross Profit	$29M	$14M	+107.9%
Operating Income	-$17M	-$16M	-6.0%
Net Income	-$14M	-$15M	+8.8%